Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19 - Top-Institutions - MDSpire

Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19

  • By

  • Esperanza Martín-Sánchez

  • Luis-Esteban Tamariz-Amador

  • Camila Guerrero

  • Anastasiia Zherniakova

  • Aintzane Zabaleta

  • Catarina Maia

  • Laura Blanco

  • Diego Alignani

  • Maria-Antonia Fortuño

  • Carlos Grande

  • Andrea Manubens

  • Jose-Maria Arguiñano

  • Clara Gomez

  • Ernesto Perez-Persona

  • Iñigo Olazabal

  • Itziar Oiartzabal

  • Carlos Panizo

  • Felipe Prosper

  • Jesus F. San-Miguel

  • Paula Rodriguez-Otero

  • Bruno Paiva

  • July 10, 2024

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Immunology
    • Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Immunotherapy
    • Oncology

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology
    • Immunology
    • Oncology

  • #4

    Johns Hopkins Medicine
    Johns Hopkins Medicine

    Baltimore, MD

    Key Differentiators

    • Hematology
    • Immunology
    • Infectious Diseases

  • #5

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematology
    • Immunotherapy
    • Oncology

Original Source(s)

Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19

  • by Esperanza Martín-Sánchez, Luis-Esteban Tamariz-Amador, Camila Guerrero, Anastasiia Zherniakova, Aintzane Zabaleta, Catarina Maia, Laura Blanco, Diego Alignani, Maria-Antonia Fortuño, Carlos Grande, Andrea Manubens, Jose-Maria Arguiñano, Clara Gomez, Ernesto Perez-Persona, Iñigo Olazabal, Itziar Oiartzabal, Carlos Panizo, Felipe Prosper, Jesus F. San-Miguel, Paula Rodriguez-Otero, Bruno Paiva

  • July 10, 2024

Related Content

Treatment Intensity in the Frontline Setting for Transplant-Ineligible Patients With Multiple Myeloma

The management of newly diagnosed transplant-ineligible multiple myeloma remains challenging, in part due to the complexity of treatment decisions for frail patients. Recent subgroup analyses provide insight into whether quadruplet therapy may offer advantages over triplet therapy in this population.

Prognostic Impact of Early Disease Progression and Early Mortality in Patients with Multiple Myeloma: A Real-World Cohort Study

Equity and representation in oncology clinical evidence for FDA-approved treatments and the impact of COVID-19